Esperante Ventures is a Netherlands based venture capital firm focused on investing in life sciences companies.
Founded in 2004 as a private investment company, Esperante Ventures is controlled by C&P Group Holdings, a privately controlled life sciences interest group.
Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer Biomarkers, Cytox, Haemostatix, Anergis, Canbex Therapeutics, Karus Therapeutics, Novacta Biosystems and Cara Therapeutics.
Esperante Ventures exited their investments in Haemostatix, Canbex Therapeutics, Thiakis, Pinnacle Biologics and Cara Therapeutics.
Esperante Ventures is a Hoofddorp, Netherlands based venture capital firm. They focus on investing in life scienceslife sciences companies, specifically in drug development, diagnostic and bio-marker tests and pharmaceutical sales.
Esperante Ventures exited their investments in Haemostatix, Canbex Therapeutics, Thiakis, Pinnacle BiologicsPinnacle Biologics and Cara Therapeutics.
Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer Biomarkers, Cytox, Haemostatix, AnergisAnergis, Canbex Therapeutics, Karus Therapeutics, Novacta Biosystems and Cara Therapeutics.
Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer BiomarkersOxford Cancer Biomarkers, Cytox, Haemostatix, Anergis, Canbex Therapeutics, Karus Therapeutics, Novacta Biosystems and Cara Therapeutics.
Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer Biomarkers, Cytox, Haemostatix, Anergis, Canbex Therapeutics, Karus TherapeuticsKarus Therapeutics, Novacta Biosystems and Cara Therapeutics.
Esperante Ventures is a Hoofddorp, NetherlandsNetherlands based venture capital firm. They focus on investing in life sciences companies, specifically in drug development, diagnostic and bio-marker tests and pharmaceutical sales.